Works by Papadopoulos, Kyriakos


Results: 98
    1
    2
    3

    Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
    By:
    • Chia-Chi Lin;
    • Calvo, Emiliano;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Sarantopoulos, John;
    • Mita, Alain C.;
    • Preston, Glenn G.;
    • Mita, Monica M.;
    • Rodon, Jordi;
    • Mays, Theresa;
    • I.-Tien Yeh;
    • O'Rourke, Pat;
    • Takimoto, Chris H.;
    • Dancey, Janet E.;
    • Chen, Helen;
    • Tolcher, Anthony W.
    Publication type:
    Article
    4

    Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.

    Published in:
    Neuro-Oncology Advances, 2023, v. 5, n. 1, p. 1, doi. 10.1093/noajnl/vdac183
    By:
    • Carneiro, Benedito A;
    • Papadopoulos, Kyriakos P;
    • Strickler, John H;
    • Lassman, Andrew B;
    • Waqar, Saiama N;
    • Chae, Young Kwang;
    • Patel, Jyoti D;
    • Shacham-Shmueli, Einat;
    • Kelly, Karen;
    • Khasraw, Mustafa;
    • Bestvina, Christine M;
    • Merrell, Ryan;
    • Huang, Kevin;
    • Atluri, Harisha;
    • Ansell, Peter;
    • Li, Rachel;
    • Jin, Janet;
    • Anderson, Mark G;
    • Reilly, Edward B;
    • Morrison-Thiele, Gladys
    Publication type:
    Article
    5
    6
    7
    8

    The order on the light cone and its induced topology.

    Published in:
    International Journal of Geometric Methods in Modern Physics, 2018, v. 15, n. 5, p. -1, doi. 10.1142/S021988781850069X
    By:
    • Papadopoulos, Kyriakos;
    • Acharjee, Santanu;
    • Papadopoulos, Basil K.
    Publication type:
    Article
    9
    10
    11
    12
    13
    14

    Poly[3-(3, 4-dihydroxyphenyl) glyceric acid] from Comfrey exerts anti-cancer efficacy against human prostate cancer via targeting androgen receptor, cell cycle arrest and apoptosis.

    Published in:
    Carcinogenesis, 2012, v. 33, n. 8, p. 1572, doi. 10.1093/carcin/bgs202
    By:
    • Sangeeta, Shrotriya;
    • Gagan, Deep;
    • Kumaraguruparan, Ramasamy;
    • Komal, Raina;
    • Vakhtang, Barbakadze;
    • Maia, Merlani;
    • Lali, Gogilashvili;
    • Lela, Amiranashvili;
    • Karen, Mulkijanyan;
    • Kyriakos, Papadopoulos;
    • Chapla, Agarwal;
    • Rajesh, Agarwal
    Publication type:
    Article
    15
    16

    Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 6, p. 1763, doi. 10.3109/10428194.2014.974040
    By:
    • Papadopoulos, Kyriakos P.;
    • Egile, Coumaran;
    • Ruiz-Soto, Rodrigo;
    • Jiang, Jason;
    • Shi, Weiliang;
    • Bentzien, Frauke;
    • Rasco, Drew;
    • Abrisqueta, Pau;
    • Vose, Julie M.;
    • Tabernero, Josep
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24

    Lack of Meaningful Effect of Ridaforolimus on the Pharmacokinetics of Midazolam in Cancer Patients: Model Prediction and Clinical Confirmation.

    Published in:
    Journal of Clinical Pharmacology, 2014, v. 54, n. 11, p. 1256, doi. 10.1002/jcph.331
    By:
    • Stroh, Mark;
    • Talaty, Jennifer;
    • Sandhu, Punam;
    • McCrea, Jacqueline;
    • Patnaik, Amita;
    • Tolcher, Anthony;
    • Palcza, John;
    • Orford, Keith;
    • Breidinger, Sheila;
    • Narasimhan, Narayana;
    • Panebianco, Deborah;
    • Lush, Richard;
    • Papadopoulos, Kyriakos P.;
    • Wagner, John A.;
    • Trucksis, Michele;
    • Agrawal, Nancy
    Publication type:
    Article
    25
    26
    27

    Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

    Published in:
    Neuro-Oncology, 2019, v. 21, n. 1, p. 106, doi. 10.1093/neuonc/noy091
    By:
    • Lassman, Andrew B;
    • Bent, Martin J van den;
    • Gan, Hui K;
    • Reardon, David A;
    • Kumthekar, Priya;
    • Butowski, Nicholas;
    • Lwin, Zarnie;
    • Mikkelsen, Tom;
    • Nabors, Louis B;
    • Papadopoulos, Kyriakos P;
    • Penas-Prado, Marta;
    • Simes, John;
    • Wheeler, Helen;
    • Walbert, Tobias;
    • Scott, Andrew M;
    • Gomez, Erica;
    • Lee, Ho-Jin;
    • Roberts-Rapp, Lisa;
    • Xiong, Hao;
    • Ansell, Peter J
    Publication type:
    Article
    28

    Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.

    Published in:
    International Journal of Cancer, 2021, v. 149, n. 2, p. 403, doi. 10.1002/ijc.33556
    By:
    • Tannir, Nizar M.;
    • Papadopoulos, Kyriakos P.;
    • Wong, Deborah J.;
    • Aljumaily, Raid;
    • Hung, Annie;
    • Afable, Manuel;
    • Kim, Jong Seok;
    • Ferry, David;
    • Drakaki, Alexandra;
    • Bendell, Johanna;
    • Naing, Aung
    Publication type:
    Article
    29
    30

    Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

    Published in:
    2018
    By:
    • Goss, Glenwood D.;
    • Vokes, Everett E.;
    • Gordon, Michael S.;
    • Gandhi, Leena;
    • Papadopoulos, Kyriakos P.;
    • Rasco, Drew W.;
    • Fischer, JuDee S.;
    • Chu, Katharine L.;
    • Ames, William W.;
    • Mittapalli, Rajendar K.;
    • Lee, Ho‐Jin;
    • Zeng, Jiewei;
    • Roberts‐Rapp, Lisa A.;
    • Loberg, Lise I.;
    • Ansell, Peter J.;
    • Reilly, Edward B.;
    • Ocampo, Christopher J.;
    • Holen, Kyle D.;
    • Tolcher, Anthony W.;
    • Lee, Ho-Jin
    Publication type:
    journal article
    31
    32
    33

    Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

    Published in:
    2017
    By:
    • Bent, Martin;
    • Gan, Hui;
    • Lassman, Andrew;
    • Kumthekar, Priya;
    • Merrell, Ryan;
    • Butowski, Nicholas;
    • Lwin, Zarnie;
    • Mikkelsen, Tom;
    • Nabors, Louis;
    • Papadopoulos, Kyriakos;
    • Penas-Prado, Marta;
    • Simes, John;
    • Wheeler, Helen;
    • Walbert, Tobias;
    • Scott, Andrew;
    • Gomez, Erica;
    • Lee, Ho-Jin;
    • Roberts-Rapp, Lisa;
    • Xiong, Hao;
    • Bain, Earle
    Publication type:
    journal article
    34

    Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

    Published in:
    2017
    By:
    • Infante, Jeffrey;
    • Patnaik, Amita;
    • Verschraegen, Claire;
    • Olszanski, Anthony;
    • Shaheen, Montaser;
    • Burris, Howard;
    • Tolcher, Anthony;
    • Papadopoulos, Kyriakos;
    • Beeram, Muralidhar;
    • Hynes, Scott;
    • Leohr, Jennifer;
    • Lin, Aimee;
    • Li, Lily;
    • McGlothlin, Anna;
    • Farrington, Daphne;
    • Westin, Eric;
    • Cohen, Roger;
    • Infante, Jeffrey R;
    • Verschraegen, Claire F;
    • Olszanski, Anthony J
    Publication type:
    journal article
    35
    36
    37
    38

    A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 5, p. 951, doi. 10.1007/s00280-014-2426-8
    By:
    • Patnaik, Amita;
    • LoRusso, Patricia;
    • Messersmith, Wells;
    • Papadopoulos, Kyriakos;
    • Gore, Lia;
    • Beeram, Muralidhar;
    • Ramakrishnan, Vanitha;
    • Kim, Amy;
    • Beyer, Joseph;
    • Mason Shih, L.;
    • Darbonne, Walter;
    • Xin, Yan;
    • Yu, Ron;
    • Xiang, Hong;
    • Brachmann, Rainer;
    • Weekes, Colin
    Publication type:
    Article
    39
    40
    41
    42
    43
    44

    A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 4, p. 567, doi. 10.1007/s00280-012-1942-7
    By:
    • Lush, Richard;
    • Patnaik, Amita;
    • Sullivan, Daniel;
    • Papadopoulos, Kyriakos;
    • Trucksis, Michele;
    • McCrea, Jacqueline;
    • Cerchio, Kristine;
    • Li, Xiaodong;
    • Stroh, Mark;
    • Selverian, Diana;
    • Orford, Keith;
    • Ebbinghaus, Scot;
    • Agrawal, Nancy;
    • Iwamoto, Marian;
    • Wagner, John;
    • Tolcher, Anthony
    Publication type:
    Article
    45
    46
    47
    48
    49
    50